ImmunoGen Inc. Daily Stock Analysis

Daily Stock Analysis, IMGN, ImmunoGen Inc, priceseries

ImmunoGen Inc. Daily Stock Analysis
Stock Information
Open
5.21
Close
5.25
High
5.39
Low
5.19
Previous Close
5.19
Daily Price Gain
0.06
YTD High
7.63
YTD High Date
Jan 3, 2022
YTD Low
4.58
YTD Low Date
Feb 24, 2022
YTD Price Change
-2.23
YTD Gain
-29.81%
52 Week High
9.62
52 Week High Date
Mar 16, 2021
52 Week Low
4.58
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-3.21
52 Week Gain
-37.94%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 30. 2016
2.04
Jan 24. 2017
2.33
15 Trading Days
14.23%
Link
LONG
Feb 23. 2017
2.61
Mar 17. 2017
3.49
16 Trading Days
33.68%
Link
LONG
May 12. 2017
4.10
May 26. 2017
4.75
10 Trading Days
15.91%
Link
LONG
Jun 19. 2017
4.91
Jul 11. 2017
6.85
15 Trading Days
39.41%
Link
LONG
Jan 9. 2018
7.40
Feb 5. 2018
8.35
18 Trading Days
12.87%
Link
LONG
Feb 14. 2018
10.15
Mar 8. 2018
10.78
15 Trading Days
6.19%
Link
LONG
Jan 4. 2019
4.94
Jan 14. 2019
5.24
6 Trading Days
6.12%
Link
LONG
Jun 27. 2019
2.05
Jul 16. 2019
2.35
12 Trading Days
14.59%
Link
LONG
Aug 5. 2019
2.50
Aug 20. 2019
2.77
11 Trading Days
10.60%
Link
LONG
Nov 1. 2019
3.04
Nov 7. 2019
3.21
4 Trading Days
5.72%
Link
LONG
Nov 22. 2019
3.35
Dec 11. 2019
3.71
12 Trading Days
10.78%
Link
LONG
Dec 16. 2019
3.89
Dec 30. 2019
5.08
9 Trading Days
30.66%
Link
LONG
Feb 10. 2020
4.81
Feb 21. 2020
5.53
8 Trading Days
14.87%
Link
LONG
May 15. 2020
4.43
May 27. 2020
4.66
7 Trading Days
5.14%
Link
LONG
Oct 2. 2020
3.87
Nov 11. 2020
5.76
28 Trading Days
48.92%
Link
LONG
Feb 5. 2021
7.69
Feb 25. 2021
8.75
13 Trading Days
13.80%
Link
LONG
Oct 28. 2021
5.92
Nov 8. 2021
6.27
7 Trading Days
5.89%
Link
Company Information
Stock Symbol
IMGN
Exchange
NasdaqGS
Company URL
http://www.immunogen.com
Company Phone
(781)895-0600
CEO
Mark J. Enyedy
Headquarters
Massachusetts
Business Address
830 WINTER ST, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000855654
About

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.

Description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading